Twitter Beğeni Hilesi

Dr. Sarah Sammons (Dr Sarah Sammons) delivered an insightful lecture on the Treatment of HER2-Positive #MetastaticBreastCancer at the #HarvardBreastCancerCourse.

Daniel Abravanel MD PhD (Daniel Abravanel, MD/PhD), delivered an excellent lecture on integrating treatment options for ER+ #MetastaticBreastCancer at today’s Breast Cancer: New Horizons, Current Controversies Course. #HarvardBreastCancerCourse.

When I was an intern, pre-rounding was one of the most stressful parts of the day. Over time I have become more efficient. Here are some tips I have learned along the way! If helpful, check out my other threads or join my newsletter (starting on Friday - 7/19/24) for more

“Could you explain how trying to get funding for clinical research in Latin America feels like with a soccer analogy?” “Say no more”

It is a pleasure to introduce the new Board and Steering Committee of the LACOG Sarcoma Group! The new formation of the group will run from 2024 to 2026, and will continue with the goal of developing new clinical and epidemiological studies with a focus on these rare neoplasms.

ETAC-S, a framework for optimising tumour-agnostic 💊 drug development and for accelerating patient access to effective therapies. 🎯

The ESMO Tumour-Agnostic Classifier and Screener (ETAC-S): a tool for assessing tumour-agnostic potential of molecularly guided therapies and for steering drug development annalsofoncology.org/article/S0923-…

ESMO announces the publication of the ESMO Tumour-Agnostic Classifier and Screener (ETAC-S), a new framework to assess the tumour-agnostic potential of #CancerTherapies with the aim to optimise the drug development process Annals of Oncology. 🔗ow.ly/rqmR50T6gHt

Screening for Tumour-Agnostic potential and rethinking drug development at ESMO - European Society for Medical Oncology

When a group of brilliant & engaged people from different hospitals, cities & countries comes together, the end result is the development of practice changing tools in oncology! So proud! Thanks Ben Westphalen Vivek Subbiah, MD George Pentheroudakis Diogo Martins Branco esmo.org/newsroom/esmo-…

📢#CancerTherapy claiming #TumourAgnostic potential❓ ✔ ORR≥20% in 2/3 of tumour types investigated (≥4) with ≥5 evaluable patients per tumour type 🔓ESMO - Eur. Oncology Tumour-Agnostic Classifier & Screener (ETAC-S) Annals of Oncology Ben Westphalen Vivek Subbiah, MD George Pentheroudakis et al

🚨🥁 Hot off the press 👉 Presenting to the world a future framework for Tissue agnostic drug development - Special article published Annals of Oncology –an X 'torial for this major milestone in #precisionMedicine ✅1/n - “The ESMO Tumour-Agnostic Classifier and Screener

Advances in precision medicine led to approval of tumour-agnostic molecularly guided therapies. The minimum requirements for claiming tumour-agnostic potential remain elusive. Different scenarios of minimum ORR, number of tumour types investigated & number of evaluable patients

The ETAC screener is a simple tool to detect tumour-agnostic potential of a cancer therapy. Emphasis on “potential”. So, if the potential is there, further clinical validation would be required.

Following a drug screening positive by ETAC-S, we propose a research and regulatory framework for validation/graduation of tumour-agnostic therapies and biomarkers.

I am commonly asked what the benchmarks are for a target-drug pair to have tumor-agnostic potential. See the new ETAC-S! Annals of Oncology ESMO - Eur. Oncology Vivek Subbiah, MD Juliana Beal, MD G Curigliano MD PhD Razelle Kurzrock, MD Sewanti Limaye 🇮🇳🇺🇸 Stefan Michiels Joaquin Mateo Niamh Coleman, MD PhD FabriceAndre Elena Garralda

Our ETAC-S paper was published in Annals of Oncology - Juliana Beal, MD (H.I.Albert Einstein) oncodaily.com/url/132174 #AnnalsOfOncology #ETACS #JulianaBeal #OncologyResearch #CancerPublications #MedicalScience #OncoDaily #Oncology #Cancer

New article in press: The ESMO Tumour-Agnostic Classifier and Screener (ETAC-S): a tool for assessing tumour-agnostic potential of molecularly guided therapies and for steering drug development. Ben Westphalen FabriceAndre Vivek Subbiah, MD